"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) (→Our Sponsors) |
||
| Line 33: | Line 33: | ||
*Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] | *Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] | ||
*Qiagen [http://www1.qiagen.com/ [Link]] | *Qiagen [http://www1.qiagen.com/ [Link]] | ||
| + | *Fisher-Scientific [http://www.fr.fishersci.com/ [Link]] | ||
|} | |} | ||
Revision as of 17:06, 19 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
| We want to acknowledge : |
Contents |
UMR CNRS 8121 from the Gustave Roussy Institute
- Lluis M. Mir
- Karim Benihoud
INSERM U872
- Srinivas Kaveri
AnyGenes
- Benyoussef Naimi
Our Sponsors
- Embassy of France in Washington [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]]
- Eurogentec [http://www.eurogentec.com/eu-home.html [Link]]
- Takara [http://www.takarabioeurope.com/ [Link]]
- Clonetec [http://www.clontech.com/ [Link]]
- Promega [http://www.promega.com/ [Link]]
- Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]]
- Qiagen [http://www1.qiagen.com/ [Link]]
- Fisher-Scientific [http://www.fr.fishersci.com/ [Link]]
